Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2016

01-01-2016 | Original Article

Hypofractionated palliative radiotherapy for bladder cancer

Authors: Piet Dirix, Sofie Vingerhoedt, Steven Joniau, Ben Van Cleynenbreugel, Karin Haustermans

Published in: Supportive Care in Cancer | Issue 1/2016

Login to get access

Abstract

Purpose

The aim of this study was to evaluate hematuria-free survival as well as acute and late toxicity after hypofractionated palliative radiotherapy for bladder cancer.

Methods and materials

Between September 2004 and January 2013, 44 patients with biopsy-proven urothelial carcinoma of the bladder were irradiated according to a palliative schedule to a total dose of 34.5 Gy in six fractions of 5.75 Gy given once a week.

Results

After a mean follow-up of 10 months, 91 % of patients were still hematuria free, with a mean hematuria-free survival of 13 months. Severe (≥ grade 3) acute and late urinary toxicity was observed in 9 and 19 % of patients, respectively.

Conclusion

This hypofractionated radiotherapy schedule appears to result in acceptable toxicity and manages successful and long-term palliation of hematuria in most patients.
Literature
1.
Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. Worl J Urol 27:289–293CrossRef
2.
3.
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306:737–745PubMedCentralCrossRefPubMed
4.
Pira E, Piolatto G, Negri E et al (2010) Bladder cancer mortality of workers exposed to aromatic amines: a 58-year follow-up. J Natl Cancer Inst 102:1096–1099CrossRefPubMed
5.
Bellmunt J, Orsola A, Wiegel T et al (2011) Bladder cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22:45–49
6.
Advanced bladder cancer meta-analysis collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927–1934CrossRef
7.
James ND, Hussain SA, Hall E et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477–1488CrossRefPubMed
8.
Shipley WU, Kaufman DS, Zehr E et al (2002) Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60:62–67CrossRefPubMed
9.
Rödel C, Weiss C, Sauer R (2006) Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24:5536–5544CrossRefPubMed
10.
Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE (2008) Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 70:456–463CrossRefPubMed
11.
Abt D, Bywater M, Engeler DS, Schmid H (2013) Therapeutic options for intractable hematuria in advanced bladder cancer. Int J Urol 20:651–660CrossRefPubMed
12.
Cihoric N, Crowe S, Eychmüller S, Aebersold DM, Ghadjar P (2012) Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy. Radiat Oncol 7:132PubMedCentralCrossRefPubMed
13.
Wildmark A, Flodgren P, Damber JE, Hellsten S, Cavallin-Ståhl E (2003) A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol 42:567–581CrossRef
14.
Maciejewski B, Majewski S (1991) Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 21:163–170CrossRefPubMed
15.
Pos FJ, Hart G, Schneider C, Sminia P (2006) Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 64:1168–1173CrossRefPubMed
16.
AJCC Cancer Staging Manual, 7th edition, Springer, New York 2010
17.
Rostom AY, Tahir S, Gershuny AR et al (1996) Once weekly irradiation for carcinoma of the bladder. Int J Radiat Oncol Biol Phys 35:289–292CrossRefPubMed
18.
Scholten AN, Leer JWH, Collins CD et al (1997) Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol 43:163–169CrossRefPubMed
19.
McLaren DB, Morrey D, Mason MD (1997) Hypofractionated radiotherapy for muscle invasive bladder cancer in elderly. Radiother Oncol 43:171–174CrossRefPubMed
20.
Jose CC, Price A, Norman A et al (1999) Hypofractionated radiotherapy for patients with carcinoma of the bladder. Clin Oncol 11:330–333CrossRef
21.
Pos FJ, van Tienhoven G, Hulshof M et al (2003) Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol 68:75–80CrossRefPubMed
22.
Kouloulias V, Tolia M, Kolliarakis N et al (2013) Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer. Int Braz J Urol 39:77–82CrossRefPubMed
23.
Lutz S, Berk L, Chang E et al (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965–976CrossRefPubMed
Metadata
Title
Hypofractionated palliative radiotherapy for bladder cancer
Authors
Piet Dirix
Sofie Vingerhoedt
Steven Joniau
Ben Van Cleynenbreugel
Karin Haustermans
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2765-y

Other articles of this Issue 1/2016

Supportive Care in Cancer 1/2016 Go to the issue

Original Article

Predicting distress among people who care for patients living longer with high-grade malignant glioma

Original Article

Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer

Original Article

Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia

Original Article

Low-level laser therapy alleviates mechanical and cold allodynia induced by oxaliplatin administration in rats

Letter to the editor

Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma

Original Article

Identifying trajectory clusters in breast cancer survivors’ supportive care needs, psychosocial difficulties, and resources from the completion of primary treatment to 8 months later
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits